These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Stocchi F Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296 [TBL] [Abstract][Full Text] [Related]
33. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
34. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191 [TBL] [Abstract][Full Text] [Related]
35. [Diagnosis and therapy of idiopathic Parkinson's disease]. Reichmann H MMW Fortschr Med; 2006 May; Spec no. 2():54, 56-8, 60-1. PubMed ID: 20104716 [TBL] [Abstract][Full Text] [Related]
36. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768 [TBL] [Abstract][Full Text] [Related]
37. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. Damier P; Tremblay L; Féger J; Hirsch EC Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093 [TBL] [Abstract][Full Text] [Related]
38. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
40. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Hauser RA Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S17-21. PubMed ID: 20082983 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]